Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching
Pediatric Dermatology · 2026
DOI: 10.1111/pde.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Shaliz Aflatooni und 7 weiteren Autor:innen. Beteiligte Einrichtung: USF Morsani College of Medicine, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Time-to-Treatment, Practice Patterns, Physicians'. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Hidradenitis suppurativa (HS) causes significant morbidity in children. Treatment patterns across sex, race, and ethnicity in pediatric HS have not been thoroughly evaluated. We aim to characterize treatment patterns in pediatric HS, including (1) time to treatment initiation, (2) first prescribed HS treatment, and (3) time to switching following initial therapy across demographic factors.
Methods
We conducted a real‐world, retrospective cohort study of patients < 18 years with a HS diagnosis, using a large U.S. national electronic health record database (2005–2025). Treatments prescribed within 1 year after HS diagnosis were categorized as systemic antibiotics, topicals, hormonal therapies, retinoids, biologics, or procedures.
Results
The cohort included 6659 children with HS (mean age 12.8 ± 2.8 years at diagnosis), 74.9% female, 37.7% White, and 56.5% non‐Hispanic/Latino. Overall, 3.2% of children received biologics. Following HS diagnosis, the mean time to treatment initiation was 15 days. The most common initial treatment was systemic antibiotics plus topical therapies. The mean time on the initial treatment regimen prior to switching was 386 days. Multivariable analyses demonstrated that girls were more likely than boys to receive any treatments, including biologics, except major procedures. Non‐White children initiated treatment sooner than White children (1 vs. 17 days, p < 0.0001). Regardless of demographic subgroup, most children remained on their initial HS treatment for a mean duration of approximately a year before switching therapies.
Conclusion
Pediatric HS care is characterized by delayed treatment escalation, antibiotic‐dominant initial therapy, and variation in treatment initiation timing across demographic groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- USF Morsani College of Medicine, Tampa, Florida, USA.
- University of California, Davis School of Medicine, Sacramento, California, USA.
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- University of California, San Diego, School of Medicine, San Diego, California, USA.
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
- David Geffen School of Medicine at the University of California, Los Angeles, USA.
ORCID-Profile: Shaliz Aflatooni, Nicole Johnsen, April W Armstrong
Zitieren
APA
Aflatooni, S., Ure, A., Smart, K., Cortes, J. A., Palma, G., Johnsen, N., Nong, Y., & Armstrong, A. W. (2026). Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching. Pediatric Dermatology. https://doi.org/10.1111/pde.70214
Vancouver
Aflatooni S, Ure A, Smart K, Cortes JA, Palma G, Johnsen N, et al. Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching. Pediatric Dermatology. 2026. doi:10.1111/pde.70214
BibTeX
@article{Aflatooni2026,
author = {Aflatooni, Shaliz and Ure, Andrea and Smart, Kimberly and Cortes, Julian A and Palma, Gabriela and Johnsen, Nicole and Nong, Yvonne and Armstrong, April W},
title = {Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70214}
}
EUVIMED